Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock surged 13% after the company reported positive interim Phase 1 data for its MRT-8102 drug, demonstrating significant reductions in ...

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment ...

EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative biotechnology company focused on developing ...

CRP levels below 2 mg/L, a threshold associated with lower cardiovascular risk. ・Safety data were favorable, with adverse events that were mild to moderate, self-resolving, and not dose-dependent.

Shares in Monte Rosa Therapeutics (NASDAQ:GLUE) climbed around 13% after the company released encouraging interim results from a Phase 1 study of its experimental drug MRT-8102, pointing to a marked ...

The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...

Rosai-Dorfman-Destombes disease (RDD) is a rare, benign histiocytic disorder, most often involving lymph nodes but showing extranodal manifestations in nearly 50% of cases, particularly in the skin ...

The gut isn’t just where food goes. It’s where information is processed, decisions are made, and resilience is built.

This review synthesizes clinical, genetic, and mechanistic evidence showing that suPAR and related uPAR fragments are ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using a patient’s own T-cells to target tumors. However, they can cause rare but potentially fatal cardiac inflammation ...

According to Towards FnB, the global functional pet food market size is evaluated at USD 3.35 billion in 2026 and is ...